SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Objective

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

https://www.clinicaltrials.gov/ct2/show/NCT02834013

Contact Phone: 218-786-3308 | 1-844-681-7944

Email: cancertrials@essentiahealth.org

Locations: Essentia Health Cancer Centers

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/08/2018

Research Study Categories

  • Adult Studies

Specialty

  • Rare Tumor
  • Cancer